Search

Your search keyword '"Welsh, A. W."' showing total 525 results
Start Over Author "Welsh, A. W." Search Limiters Available in Library Collection
525 results on '"Welsh, A. W."'

1. Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3

Author

Hu, Yun, Paris, Sébastien, Sahoo, Narayan, Wang, Qi, Wang, Qianxia, Barsoumian, Hampartsoum B., Huang, Ailing, Da Silva, Jordan, Bienassis, Célia, Leyton, Claudia S. Kettlun, Voss, Tiffany A., Masrorpour, Fatemeh, Riad, Thomas, Leuschner, Carola, Puebla-Osorio, Nahum, Gandhi, Saumil, Nguyen, Quynh-Nhu, Wang, Jing, Cortez, Maria Angelica, and Welsh, James W.

Published
2024
Full Text
View/download PDF

5. Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy

Author

Hu, Yun, Revenko, Alexey, Barsoumian, Hampartsoum, Bertolet, Genevieve, Fowlkes, Natalie Wall, Maazi, Hadi, Green, Morgan Maureen, He, Kewen, Sezen, Duygu, Voss, Tiffany A., Leyton, Claudia S Kettlun, Masrorpour, Fatemeh, Rafiq, Zahid, Puebla-Osorio, Nahum, Leuschner, Carola, MacLeod, Robert, Cortez, Maria Angelica, and Welsh, James W.

Published
2024
Full Text
View/download PDF

8. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors.

Author

Siu, Lillian, Brody, Joshua, Gupta, Shilpa, Marabelle, Aurélien, Jimeno, Antonio, Munster, Pamela, Grilley-Olson, Juneko, Rook, Alain H, Hollebecque, Antoine, Wong, Rebecca KS, Welsh, James W, Wu, Yuling, Morehouse, Christopher, Hamid, Oday, Walcott, Farzana, Cooper, Zachary A, Kumar, Rakesh, Ferté, Charles, and Hong, David S

Subjects
CD8-positive t-lymphocytes, Th1-Th2 balance, combination, drug therapy, immunotherapy, radioimmunotherapy
Abstract

BackgroundMEDI9197 is an intratumorally administered toll-like receptor 7 and 8 agonist. In mice, MEDI9197 modulated antitumor immune responses, inhibited tumor growth and increased survival. This first-time-in-human, phase 1 study evaluated MEDI9197 with or without the programmed cell death ligand-1 (PD-L1) inhibitor durvalumab and/or palliative radiation therapy (RT) for advanced solid tumors.Patients and methodsEligible patients had at least one cutaneous, subcutaneous, or deep-seated lesion suitable for intratumoral (IT) injection. Dose escalation used a standard 3+3 design. Patients received IT MEDI9197 0.005-0.055 mg with or without RT (part 1), or IT MEDI9197 0.005 or 0.012 mg plus durvalumab 1500 mg intravenous with or without RT (part 3), in 4-week cycles. Primary endpoints were safety and tolerability. Secondary endpoints included pharmacokinetics, pharmacodynamics, and objective response based on Response Evaluation Criteria for Solid Tumors version 1.1. Exploratory endpoints included tumor and peripheral biomarkers that correlate with biological activity or predict response.ResultsFrom November 2015 to March 2018, part 1 enrolled 35 patients and part 3 enrolled 17 patients; five in part 1 and 2 in part 3 received RT. The maximum tolerated dose of MEDI9197 monotherapy was 0.037 mg, with dose-limiting toxicity (DLT) of cytokine release syndrome in two patients (one grade 3, one grade 4) and 0.012 mg in combination with durvalumab 1500 mg with DLT of MEDI9197-related hemorrhagic shock in one patient (grade 5) following liver metastasis rupture after two cycles of MEDI9197. Across parts 1 and 3, the most frequent MEDI9197-related adverse events (AEs) of any grade were fever (56%), fatigue (31%), and nausea (21%). The most frequent MEDI9197-related grade ≥3 events were decreased lymphocytes (15%), neutrophils (10%), and white cell counts (10%). MEDI9197 increased tumoral CD8+ and PD-L1+ cells, inducing type 1 and 2 interferons and Th1 response. There were no objective clinical responses; 10 patients in part 1 and 3 patients in part 3 had stable disease ≥8 weeks.ConclusionIT MEDI9197 was feasible for subcutaneous/cutaneous lesions but AEs precluded its use in deep-seated lesions. Although no patients responded, MEDI9197 induced systemic and intratumoral immune activation, indicating potential value in combination regimens in other patient populations.Trial registration numberNCT02556463.

Published
2020

11. Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer

Author

Hu, Yun, Paris, Sébastien, Bertolet, Genevieve, Barsoumian, Hampartsoum B., He, Kewen, Sezen, Duygu, Chen, Dawei, Wasley, Mark, SILVA, Jordan DA, Mitchell, Joylise A., Voss, Tiffany A., Masrorpour, Fatemeh, Leyton, Claudia Kettlun, Yang, Liangpeng, Leuschner, Carola, Puebla-Osorio, Nahum, Gandhi, Saumil, Nguyen, Quynh-Nhu, Cortez, Maria Angelica, and Welsh, James W.

Published
2022
Full Text
View/download PDF

12. Consensus protocol for management of early and late twin–twin transfusion syndrome: Delphi study

Author

Krispin, E., primary, Javinani, A., additional, Odibo, A., additional, Carreras, E., additional, Emery, S. P., additional, Sepulveda Gonzalez, G., additional, Habli, M., additional, Hecher, K., additional, Ishii, K., additional, Miller, J., additional, Papanna, R., additional, Johnson, A., additional, Khalil, A., additional, Kilby, M. D., additional, Lewi, L., additional, Bennasar Sans, M., additional, Otaño, L., additional, Zaretsky, M. V., additional, Sananes, N., additional, Turan, O. M., additional, Slaghekke, F., additional, Stirnemann, J., additional, Van Mieghem, T., additional, Welsh, A. W., additional, Yoav, Y., additional, Chmait, R., additional, and Shamshirsaz, A. A., additional

Published
2024
Full Text
View/download PDF

14. Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC

Author

Welsh, James W., Heymach, John V., Guo, Chunxiao, Menon, Hari, Klein, Katherine, Cushman, Taylor R., Verma, Vivek, Hess, Kenneth R., Shroff, Girish, Tang, Chad, Skoulidis, Ferdinandos, Jeter, Melenda, Comeaux, Nathan, Patel, Roshal R., Chen, Dawei, Ozgen, Tugce, Nguyen, Quynh-Nhu, Chang, Joe Y., Altan, Mehmet, Zhang, Jianjun, Papadimitrakopoulou, Vassiliki A., Simon, George R., Byers, Lauren A., and Glisson, Bonnie

Published
2020
Full Text
View/download PDF

15. Functional Domains of Substance Use and their Implications to Trauma: A Systematic Review of Neuroimaging Studies.

Author

Hinojosa, Cecilia A., Sitar, Siara I., Zhao, Joshua C., Barbosa, Joshua D., Hien, Denise A., Welsh, Justine W., Fani, Negar, and van Rooij, Sanne J.H.

Subjects
BRAIN physiology, SUBSTANCE abuse risk factors, INJURY complications, RISK assessment, SUBSTANCE abuse, TASK performance, AMYGDALOID body, RESEARCH funding, BRAIN, NEURAL pathways, FUNCTIONAL assessment, PREFRONTAL cortex, FUNCTIONAL status, EMOTIONS, MAGNETIC resonance imaging, POSITRON emission tomography, SYSTEMATIC reviews, REWARD (Psychology), MEDLINE, LARGE-scale brain networks, NEURORADIOLOGY, ATTRIBUTION (Social psychology), ALCOHOLISM, TOBACCO products, CANNABIS (Genus), HIPPOCAMPUS (Brain), ONLINE information services
Abstract

Substance use disorder (SUD) is a significant health problem, and trauma exposure is a known risk factor for the escalation of substance use. However, the shared neural mechanisms through which trauma is associated with substance use are still unknown. Therefore, we systematically review neuroimaging studies focusing on three domains that may contribute to the overlapping mechanisms of SUD and trauma—reward salience, negative emotionality, and inhibition. Using PRISMA guidelines, we identified 45 studies utilizing tasks measuring these domains in alcohol, tobacco, and cannabis use groups. Greater reward, lesser regulation of inhibitory processes, and mixed findings of negative emotionality processes in individuals who use substances versus controls were found. Specifically, greater orbitofrontal cortex, ventral tegmental area, striatum, amygdala, and hippocampal activation was found in response to reward-related tasks, and reduced activation was found in the inferior frontal gyrus and hippocampus in response to inhibition-related tasks. Importantly, no studies in trauma-exposed individuals met our review criteria. Future studies examining the role of trauma-related factors are needed, and more studies should explore inhibition- and negative-emotionality domains in individuals who use substances to uncover clinically significant alterations in these domains that place an individual at greater risk for developing a SUD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer

Author

Welsh, James W., Heymach, John V., Chen, Dawei, Verma, Vivek, Cushman, Taylor R., Hess, Kenneth R., Shroff, Girish, Tang, Chad, Skoulidis, Ferdinandos, Jeter, Melenda, Menon, Hari, Nguyen, Quynh-Nhu, Chang, Joe Y., Altan, Mehmet, Papadimitrakopoulou, Vassiliki A., Simon, George R., Raju, Uma, Byers, Lauren, and Glisson, Bonnie

Published
2020
Full Text
View/download PDF

21. The inherited KRAS-variant as a biomarker of Cetuximab Response in NSCLC

Author

Weidhaas, Joanne B, primary, Hu, Chen, additional, Komaki, Ritsuko, additional, Masters, Gregory A, additional, Blumenschein, George R, additional, Chang, Joe Y., additional, Lu, Bo, additional, Dicker, Adam P., additional, Bogart, Jeffrey A, additional, Garces, Yolanda I, additional, Narayan, Samir, additional, Robinson, Clifford G., additional, Kavadi, Vivek S, additional, Greenberger, Joel S, additional, Koprowski, Christopher D, additional, Welsh, James W., additional, Gore, Elizabeth, additional, MacRae, Robert M, additional, Paulus, Rebecca, additional, and Bradley, Jeffrey, additional

Published
2023
Full Text
View/download PDF

22. Abstract PR05: Changing the radiation and immune-oncology paradigm in patients with head and neck squamous cell carcinoma (HNSCC) with the radioenhancer NBTXR3: From bench to bedside

Author

Shen, Colette J., primary, Tourneau, Christophe Le, additional, Takacsi-Nagy, Zoltán, additional, Liem, Xavier, additional, Frakes, Jessica, additional, Niu, Jiaxin, additional, Weiss, Jared, additional, Caudell, Jimmy, additional, Hu, Yun, additional, Welsh, James W., additional, Paris, Sebastien, additional, Debard, Anais, additional, Said, Patricia, additional, Tyan, Pavel, additional, Seiwert, Tanguy Y., additional, Papai, Zsuzsanna, additional, Vivar, Omar I., additional, Farber, Leonard A., additional, and Rosenberg, Ari, additional

Published
2023
Full Text
View/download PDF

23. Bone morphogenetic protein 7 promotes resistance to immunotherapy

Author

Cortez, Maria Angelica, Masrorpour, Fatemeh, Ivan, Cristina, Zhang, Jie, Younes, Ahmed I., Lu, Yue, Estecio, Marcos R, Barsoumian, Hampartsoum B., Menon, Hari, Caetano, Mauricio da Silva, Ramapriyan, Rishab, Schoenhals, Jonathan E., Wang, Xiaohong, Skoulidis, Ferdinandos, Wasley, Mark D., Calin, George, Hwu, Patrick, and Welsh, James W.

Published
2020
Full Text
View/download PDF

25. Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection

Author

Hu, Yun, primary, Paris, Sébastien, additional, Sahoo, Narayan, additional, Bertolet, Genevieve, additional, Wang, Qi, additional, Wang, Qianxia, additional, Barsoumian, Hampartsoum B., additional, Da Silva, Jordan, additional, Huang, Ailing, additional, Doss, Denaha J., additional, Pollock, David P., additional, Hsu, Ethan, additional, Selene, Nanez, additional, Leyton, Claudia S. Kettlun, additional, Voss, Tiffany A., additional, Masrorpour, Fatemeh, additional, Ganjoo, Shonik, additional, Leuschner, Carola, additional, Pietz, Jordan T., additional, Puebla-Osorio, Nahum, additional, Gandhi, Saumil, additional, Nguyen, Quynh-Nhu, additional, Wang, Jing, additional, Cortez, Maria Angelica, additional, and Welsh, James W., additional

Published
2023
Full Text
View/download PDF

26. Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial

Author

Welsh, James W., Seyedin, Steven N., Allen, Pamela K., Hofstetter, Wayne L., Ajani, Jaffer A., Chang, Joe Y., Gomez, Daniel R., Amini, Arya, Swisher, Stephen G., Blum, Mariela A., Younes, Ahmed I., Nguyen, Quynh-Nhu, Minsky, Bruce D., Erasmus, Jeremy J., Lee, Jeffrey H., Bhutani, Manoop, and Komaki, Ritsuko U.

Published
2017
Full Text
View/download PDF

29. WISP Genes are Members of the Connective Tissue Growth Factor Family that are Up-Regulated in Wnt-1-Transformed Cells and Aberrantly Expressed in Human Colon Tumors

Author

Pennica, Diane, Swanson, Todd A., Welsh, James W., Roy, Margaret A., Lawrence, David A., Lee, James, Brush, Jennifer, Taneyhill, Lisa A., Deuel, Bethanne, Lew, Michael, Watanabe, Colin, Cohen, Robert L., Melhem, Mona F., Finley, Gene G., Quirke, Phil, Goddard, Audrey D., Hillan, Kenneth J., Gurney, Austin L., Botstein, David, and Levine, Arnold J.

Published
1998

31. Abstract 2415: NBTXR3 radio-enhancing nanoparticle achieves a more robust antitumor immune response when combined with proton radiotherapy than photon radiotherapy

Author

Hu, Yun, primary, Paris, Sébastien, additional, Sahoo, Narayan, additional, Wang, Qi, additional, Wang, Qianxia, additional, Barsoumian, Hampartsoum B., additional, Da Silva, Jordan, additional, Bienassis, Célia, additional, Huang, Ailing, additional, Puebla-Osorio, Nahum, additional, Gandhi, Saumil, additional, Nguyen, Quynh-Nhu, additional, Wang, Jing, additional, Cortez, Maria A., additional, and Welsh, James W., additional

Published
2023
Full Text
View/download PDF

34. Radiation therapy modulates tumor physical characteristics to reduce intratumoral pressure and enhance intratumoral drug delivery and retention

Author

Sezen, Duygu (ORCID 0000-0002-4505-2280 & YÖK ID 170535), Barsoumian, Hampartsoum B.; Sheth, Rahul A.; Ramapriyan, Rishab; Hsu, Ethan; Gagea, Mihai; Crowley, Kaitlyn; Williams, Malea; Welsh, James W., School of Medicine, Sezen, Duygu (ORCID 0000-0002-4505-2280 & YÖK ID 170535), Barsoumian, Hampartsoum B.; Sheth, Rahul A.; Ramapriyan, Rishab; Hsu, Ethan; Gagea, Mihai; Crowley, Kaitlyn; Williams, Malea; Welsh, James W., and School of Medicine

Abstract

Purpose: high intratumoral pressure, caused by tumor cell-to-cell interactions, interstitial fluid pressure, and surrounding stromal composition, plays a substantial role in resistance to intratumoral drug delivery and distribution. Radiation therapy (XRT) is commonly administered in conjunction with different intratumoral drugs, but assessing how radiation can reduce pressure locally and help intratumoral drug administration and retention is important. Methods and Materials: 344SQ-parental or 344SQ-anti-programmed cell death protein 1-resistant lung adenocarcinoma cells were established in 129Sv/Ev mice, and irradiated with either 1 Gy × 2, 5 Gy × 3, 8 Gy × 3, 12 Gy × 3, or 20 Gy × 1. Intratumoral pressure was measured every 3 to 4 days after XRT. Contrast dye was injected into the tumors 3- and 6-days after XRT, and imaged to measure drug retention. Results: in the 344SQ-parental model, low-dose radiation (1 Gy × 2) created an early window of reduced intratumoral pressure 1 to 3 days after XRT compared with untreated control. High-dose stereotactic radiation (12 Gy × 3) reduced intratumoral pressure 3 to 12 days after XRT, and 20 Gy × 1 showed a delayed pressure reduction on day 12. Intermediate doses of radiation did not significantly affect intratumoral pressure. In the more aggressive 344SQ-anti-programmed cell death protein 1-resistant model, low-dose radiation reduced pressure 1 to 5 days after XRT, and 12 Gy × 3 reduced pressure 1 to 3 days after XRT. Moreover, both 1 Gy × 2 and 12 Gy × 3 significantly improved drug retention 3 days after XRT; however, there was no significance detected 6 days after XRT. Lastly, a histopathologic evaluation showed that 1 Gy × 2 reduced collagen deposition within the tumor, and 12 Gy × 3 led to more necrotic core and higher extracellular matrix formation in the tumor periphery. Conclusions: optimized low-dose XRT, as well as higher stereotactic XRT regimen led to a reduction in intratumoral pressure and increased drug retenti, Sources of support: Bristol Myers Squibb funded this work.

Published
2023

35. Five-year overall survival with ipilimumab and stereotactic ablative radiotherapy for metastatic disease

Author

Sezen, Duygu (ORCID 0000-0002-4505-2280 & YÖK ID 170535), He, Kewen; Hong, David S.; Tang, Chad; Cox, Livia; Maleki, Aurian; Bertolet, Genevieve; Nguyen, Quynh-Nhu; Comeaux, Nathan I.; Schuda, Lily; Chen, Dawei; Welsh, James W., School of Medicine, Sezen, Duygu (ORCID 0000-0002-4505-2280 & YÖK ID 170535), He, Kewen; Hong, David S.; Tang, Chad; Cox, Livia; Maleki, Aurian; Bertolet, Genevieve; Nguyen, Quynh-Nhu; Comeaux, Nathan I.; Schuda, Lily; Chen, Dawei; Welsh, James W., and School of Medicine

Abstract

Purpose: ipilimumab plus stereotactic ablative radiotherapy (SABR) demonstrate satisfactory short-term clinical benefit and low toxicities in metastatic cancers. Here, we report the 5-year overall survival (OS) rates for patients with metastatic disease treated with this combined-modality therapy in a phase II trial (NCT02239900). Methods and materials: SABR was delivered to patients with metastatic lesions in the liver and lung either during the first dose (concurrent) or 1 week after the second dose (sequential) of ipilimumab (every 3 weeks for 4 cycles). SABR was administered to liver or lung metastases as 50 Gy in 4 fractions or 60 Gy in 10 fractions, considering the tumor location. The OS rates at 12, 36, and 60 months were estimated by the Kaplan-Meier method; subgroup analyses of progression-free survival (PFS) and OS by SABR-targeted lesions (liver/lung) were performed by log-rank tests. Results: a total of 106 patients were enrolled in this long-term follow-up analysis. At the median follow-up time of 15.32 months (range, 0.97–82.13 months), the median PFS was 6.52 months (95% CI, 5.86–7.14) and the median OS was 15.32 months (95% CI,13.03–17.23). The 12-, 36-, and 60-month OS rates were 61%, 23%, and 15%, respectively. There was a significant difference in OS between cohorts (P = 0.039), with a stronger response observed in lung-treated subgroups. Patients who had received sequential fractions (50 Gy/4f) to the lung had improved OS compared to those who had received sequential fractions (18.29 vs 8.9 months, P = 0.043) to the liver. Subgroup analysis of SABR-targeted lesions showed that lung-targeted groups had significantly longer PFS (6.87 months vs. 5.63 months, P = 0.034) and OS (18.67 months vs. 13.63 months, P = 0.013) compared to liver-targeted groups. The sequence did not affect the outcomes of PFS and OS. Exploratory analyses showed that SABR-targeted lesions and smoking history comprised an independent risk factor for OS. Conclusions: updated 5-y, Funding text 1: Dr. Hong declares grants from AbbVie, Aldi- Norte, Astra-Zeneca, BMS, Daiichi-Sankyo, Eisai, Fate Therapuetics, Genmab, GSK, Ignyta, Kite, Kyowa, Eli Lilly, LOXO, Merk, MedImmune Mirati, miRNA, Molecular Templates, Mologen, NCI-CTEP, Novartis, Seattle Genetics, Turning Point Therapeutics; personal fees from Alpha Insights, Axiom, Baxter, eCancer, GLG, Group H, Guidepoint, Liberium, Medscape, Numab, Oncology Education Pro- ject Association, Prime Oncology, Trieza Therapuetics, WebMD; grants and personal fees from Adaptimmune, Amgen, Bayer, Genentech, Infinity, Pfizer, Takeda. Non-financial support from AACR, ASCO, POET, CCLO, SITC; advisor for Molecular Match, OncoResponse, Presagia Inc. Dr. Tang is an Andrew Sabin Fellow. He has received personal fees from Bayer and royalties from Wolter Kluwer publishing company. Additional grant support from DOD and CPRIT. Dr. Welsh reports research support from GlaxoSmithKline, Bristol Meyers Squibb, Merck, Nanobiotix, RefleXion, Alkermes, Artidis, Mavu Pharma, Takeda, and Checkmate Pharmaceuticals. Dr. Welsh serves on the scientific advisory board for Legion Healthcare Partners, RefleXion Medical, MolecularMatch, Merck, AstraZeneca, Aileron Therapeutics, OncoResponse, Checkmate Pharmaceuticals, Mavu Pharma, Alpine Immune Sciences, Ventana Medical Systems, Nanobiotix, China Medical Tribune, GI Innovation, Genentech and Nanorobotics. JWW is on Speaking Engagements for Ventana Medical Systems, US Oncology, Alkermes, and Boehringer Ingelheim. He is co-founder of Healios, MolecularMatch, OncoResponse and serves as an advisor to Astra Zeneca, OncoResponse, Merck, MolecularMatch, Incyte, Aileron and Nanobiotix. Dr. Welsh Dr. Welsh holds stock or ownership in Alpine Immune Sciences, Checkmate Pharmaceuticals, Healios, Mavu Pharma, Legion Healthcare Partners, MolecularMatch, Nanorobotics, OncoResponse, and RefleXion. Dr. Welsh has accepted honoraria in the form of travel costs from Nanobiotix, RefleXion, Varian, Shandong

Published
2023

38. Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy

Author

Menon, Hari, Chen, Dawei, Ramapriyan, Rishab, Verma, Vivek, Barsoumian, Hampartsoum B., Cushman, Taylor R., Younes, Ahmed I., Cortez, Maria A., Erasmus, Jeremy J., de Groot, Patricia, Carter, Brett W., Hong, David S., Glitza, Isabella C., Ferrarotto, Renata, Altan, Mehmet, Diab, Adi, Chun, Stephen G., Heymach, John V., Tang, Chad, Nguyen, Quynh N., and Welsh, James W.

Published
2019
Full Text
View/download PDF

41. Pain is reduced by transcutaneous cervical vagus nerve stimulation and correlated with cardiorespiratory variability measures in the context of opioid withdrawal

Author

Gazi, Asim H., primary, Harrison, Anna B., additional, Lambert, Tamara P., additional, Nawar, Afra, additional, Obideen, Malik, additional, Driggers, Emily G., additional, Vaccarino, Viola, additional, Shah, Amit J., additional, Rozell, Christopher J., additional, Bikson, Marom, additional, Welsh, Justine W., additional, Inan, Omer T., additional, and Bremner, J. Douglas, additional

Published
2022
Full Text
View/download PDF

42. NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model

Author

Hu, Yun, primary, Paris, Sébastien, additional, Bertolet, Genevieve, additional, Barsoumian, Hampartsoum B., additional, Wang, Qi, additional, Da Silva, Jordan, additional, Patel, Nalini B., additional, Nguyen, Nguyen, additional, Doss, Denaha J., additional, Huang, Ailing, additional, Hsu, Ethan, additional, Leyton, Claudia S. Kettlun, additional, Voss, Tiffany A., additional, Masrorpour, Fatemeh, additional, Leuschner, Carola, additional, Pietz, Jordan T., additional, Puebla-Osorio, Nahum, additional, Gandhi, Saumil, additional, Nguyen, Quynh-Nhu, additional, Wang, Jing, additional, Cortez, Maria Angelica, additional, and Welsh, James W., additional

Published
2022
Full Text
View/download PDF

43. Leveraging Accelerometry as a Prognostic Indicator for Increase in Opioid Withdrawal Symptoms

Author

Lambert, Tamara P., primary, Gazi, Asim H., additional, Harrison, Anna B., additional, Gharehbaghi, Sevda, additional, Chan, Michael, additional, Obideen, Malik, additional, Alavi, Parvaneh, additional, Murrah, Nancy, additional, Shallenberger, Lucy, additional, Driggers, Emily G., additional, Alvarado Ortega, Rebeca, additional, Washington, Brianna, additional, Walton, Kevin M., additional, Tang, Yi-Lang, additional, Gupta, Rahul, additional, Nye, Jonathon A., additional, Welsh, Justine W., additional, Vaccarino, Viola, additional, Shah, Amit J., additional, Bremner, J. Douglas, additional, and Inan, Omer T., additional

Published
2022
Full Text
View/download PDF

45. The potential of biology-guided radiation therapy in thoracic cancer: A preliminary treatment planning study

Author

Seyedin, Steven N., primary, Bassalow, Rostem, additional, Mawlawi, Osama R., additional, Turner, Lehendrick M., additional, Patel, Roshal R., additional, Mazin, Samuel R., additional, Oderinde, Oluwaseyi M., additional, Voronenko, Yevgen, additional, Wages, Cody A., additional, Olcott, Peter D., additional, Chang, Joe Y., additional, Balter, Peter A., additional, and Welsh, James W., additional

Published
2022
Full Text
View/download PDF

46. Pulsed radiotherapy to mitigate high tumor burden and generate immune memory

Author

Sezen, Duygu, primary, Barsoumian, Hampartsoum B., additional, He, Kewen, additional, Hu, Yun, additional, Wang, Qi, additional, Abana, Chike O., additional, Puebla-Osorio, Nahum, additional, Hsu, Ethan Y., additional, Wasley, Mark, additional, Masrorpour, Fatemeh, additional, Wang, Jing, additional, Cortez, Maria Angelica, additional, and Welsh, James W., additional

Published
2022
Full Text
View/download PDF

47. Transcutaneous cervical vagus nerve stimulation reduces behavioral and physiological manifestations of withdrawal in patients with opioid use disorder: A double-blind, randomized, sham-controlled pilot study

Author

Gazi, Asim H., primary, Harrison, Anna B., additional, Lambert, Tamara P., additional, Obideen, Malik, additional, Alavi, Parvaneh, additional, Murrah, Nancy, additional, Shallenberger, Lucy, additional, Driggers, Emily G., additional, Ortega, Rebeca Alvarado, additional, Washington, Brianna P., additional, Walton, Kevin M., additional, Welsh, Justine W., additional, Vaccarino, Viola, additional, Shah, Amit J., additional, Tang, Yi-Lang, additional, Gupta, Rahul, additional, Back, Sudie E., additional, Inan, Omer T., additional, and Bremner, J. Douglas, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results